Quinoline and Phthalimide Substituted Silicon Phthalocyanines as Multi‐Target Inhibitors of Cholinesterases and Carbonic Anhydrases Authors: Seda Ünlü, Zeynep Köksal, Kevser Kübra Kırboğa, Fikriye Tuncel Elmalı Published: 2026 ABSTRACT ABSTRACTTwo novel axially substituted silicon phthalocyanines bearing 5,7‐dichloro‐8‐hydroxy‐2‐methylquinoline (1a) and N‐(hydroxymethyl)phthalimide (2a) moieties were synthesized and characterized by UV‐Vis, FT‐IR, 1H NMR, and mass spectrometry techniques. The biological potential of the synthesized compounds was evaluated through in vitro inhibition studies against acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and human carbonic anhydrase isoenzymes I and II (hCA I and hCA II). IC50 values were determined as 91.28 ± 25.21, 43.31 ± 20.35, 8.50 ± 2.80 and 23.35 ± 12.98 µM, for compound 1a, and 2.78 ± 1.05, 4.88 ± 1.50, 0.94 ± 1.06 and 4.15 ± 3.01 µM for compound 2a against AChE, BChE, hCA I, and hCA II enzymes respectively. Compound 2a exhibited remarkable inhibitory activity. Molecular docking results supported the experimental findings, indicating that compound 2a exhibited significantly higher inhibitory potency than compound 1a. Structure‐activity relationship analysis demonstrated that compound 2a exhibits improved enzyme inhibition. The combined experimental and computational findings showed that compound 2a is a promising multifunctional enzyme inhibitor. Compound 2a exhibited remarkable inhibitory activity across all targets. Molecular docking supported the experimental findings, with compound 2a showing more favorable Vinardo binding affinities (−8.11, −3.94, −7.39, and −7.15 kcal/mol against AChE, BChE, hCA I, and hCA II, respectively) than compound 1a, primarily through additional hydrogen‐bonding interactions provided by its phthalimide groups. The docking protocol was validated by redocking the co‐crystallized ligands, which reproduced the crystallographic poses with RMSD values below 2.0 Å for all targets. DFT calculations revealed narrow HOMO‐LUMO energy gaps (0.666 eV for 1a and 0.881 eV for 2a), consistent with the high reactivity of the phthalocyanine core, while in silico ADMET analysis indicated favorable toxicity profiles for both compounds. The combined experimental and computational findings identify compound 2a as a promising multifunctional enzyme inhibitor. Introduction Phthalocyanines are class of macrocyclic compounds studied in many fields such as gas sensors [1, 2], non linear optics [3, 4], liquid crystals [5, 6], photodynamic therapy [7, 8] and enzyme inhibition [9, 10]. Among them, silicon phthalocyanines have attracted considerable attention due to their axial substitution capability, high thermal and chemical stability, and favorable photophysical properties, which make them promising candidates for various advanced technological and biological applications [11, 12, 13]. Quinoline derivatives have a wide range of pharmacological activities [14], including acetylcholinesterase and carbonic anhydrase inhibition [15, 16]. Phthalocyanine complexes have also been reported as effective paraoxonase inhibitors, further supporting the enzyme‐inhibitory potential of this macrocyclic scaffold [17, 18]. Similarly, phthalimide‐based compounds have demonstrated notable biological activities and have been reported to improve binding affinity through hydrogen bonding and hydrophobic interactions within enzyme active sites [19, 20]. Cholinesterases ‐ acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) ‐ play an important role in the hydrolysis of the neurotransmitter acetylcholine and are key therapeutic targets in the treatment of neurodegenerative disorders such as Alzheimer's disease [21, 22, 23]. Carbonic anhydrases (CAs) are zinc‐containing metalloenzymes that play roles in various physiological processes, including pH regulation, respiration and ion transport [24, 25]. Inhibition of human carbonic anhydrase isoenzymes I and II (hCA I and hCA II) has gained attention in the management of diseases such as glaucoma, epilepsy, and cancer [26, 27, 28]. The present study reports the synthesis and characterization of two novel axially 5,7‐dichloro‐8‐hydroxy‐2‐methylquinoline and N‐(hydroxymethyl)phthalimide moieties substituted silicon phthalocyanines. The inhibitory activities of the synthesized compounds against AChE, BChE, hCA I, and hCA II were evaluated. AChE, BChE, hCA I, and hCA II were selected as target enzymes because of their therapeutic relevance and their involvement in various pathological processes. The inhibition of these enzymes has attracted considerable attention in the development of novel therapeutic agents. Furthermore, molecular docking studies were performed to elucidate the binding modes and key interactions responsible for enzyme inhibition. Density functional theory (DFT) calculations were performed to investigate the electronic properties of the compounds, and in silico ADMET analyses were conducted to evaluate their pharmacokinetic and toxicity profiles. Through this combined experimental and computational approach, this work aims to provide valuable insights into the structure‐activity relationships of axially substituted silicon phthalocyanines and to identify promising candidates for further development as multifunctional enzyme inhibitors. Similar strategies combining synthesis, cholinesterase or carbonic anhydrase inhibition assays, molecular docking, and DFT analysis have recently been reported for other heterocyclic scaffolds, including Schiff bases, hydrazones and oxadiazole thioeters [29, 30, 31, 32]. Experimental Synthesis Synthesis of 5,7‐Dichloro‐8‐hydroxy‐2‐methylquinoline Substituted Silicon Phthalocyanine (1a) 0.15 g (6.54 × 10−4 mol) of 5,7‐dichloro‐8‐hydroxy‐2‐methylquinoline, 0.20 g (3.27 × 10−4 mol) of SiPcCl2, and 0.016 g (6.54 × 10−4 mol) of NaH were mixed in 25 mL of toluene and heated at 110°C under reflux with stirring under argon atmosphere. After completion of the reaction, the mixture was cooled to room temperature and the solvent was removed using a rotary evaporator. Compound 1a was readily soluble in common organic solvents such as CHCl3, THF, DMF and DMSO. The product was purified by column chromatography using chloroform/ethyl acetate as the eluent (aluminum oxide, CHCl3:C4H8O2; 100:5, v/v). FT‐IR (ATR); cm−1: 3065 (Ar‐CH), 2920, 2850 (R‐CH), 1602 (C = N), 1578, 1524 (C = C), 1494 (C‐C), 1333 (C‐N), 1079 (Si‐O‐C). UV‐Vis; λmax, nm: 690. 1H NMR (CDCl3); δ: 9.44‐9.42 (m, 8H, Ar‐H; Hα protons), 8.24‐8.22 (m, 8H, Ar‐H; Hβ protons), 7.28‐7.26 (d, J ≈ 7.27 Hz, 2H, Ar‐H), 6.26‐6.24 (d, J ≈ 6.25 Hz, 2H, Ar‐H), 6.00 (s, 2H, Ar‐H), 2.27 (s, 6H, ‐CH3). 13C NMR (CDCl3); δ: 155.97, 148.58, 148.32, 134.99 (Quaterner C), 129.78, 129.69, 129.51, 123.99, 122.47 (Ar‐CH), 121.13, 119.67 (Quaterner C), 119.30 (Ar‐CH), 23.24 (‐CH3). MS (MALDI‐TOF MS); m/z: Calc.: 994.749 [C52H28Cl4N10O2Si], Found: 767.223 [M‐C10H6Cl2NO]+, (Q‐TOF MS); m/z: 995.1196 [M + H]+. Synthesis of N‐(Hydroxymethyl)Phthalimide Substituted Silicon Phthalocyanine (2a) 0.11 g (6.54 × 10−4 mol) of N‐(hydroxymethyl)phthalimide, 0.20 g (3.27 × 10−4 mol) of SiPcCl2, and 0.016 g (6.54 × 10−4 mol) of NaH were mixed in 25 mL of toluene and heated at 110°C under reflux with stirring under argon atmosphere. After completion of the reaction, the mixture was cooled to room temperature and the solvent was removed using a rotary evaporator. Compound 2a was found to be soluble in CHCl3, DMSO, DMF and methanol. The product was purified by washing with methanol. FT‐IR (ATR); cm−1: 3057 (Ar‐CH), 2926 (R‐CH), 1721 (C = O), 1609 (C = N), 1532, 1519 (C = C), 1471 (C‐C), 1334 (C‐N), 1078 (Si‐O‐C). UV‐Vis; λmax, nm: 694. 1H NMR (CDCl3); δ: 9.65 (s, 8H, Ar‐H; Hα protons), 8.34 (s, 8H, Ar‐H; Hβ protons), 7.76‐7.67 (d, J ≈ 7.72 Hz, 8H, Ar‐H), 5.34 (s, 4H, O‐CH2). 13C NMR (CDCl3); δ: 168.38 (C = O), 155.97 (Quaterner C), 134.36, 133.95 (Ar‐CH), 132.16 (Quaterner C), 123.64 123.34 (Ar‐CH), 55.68 (O‐CH2‐N). MS (MALDI‐TOF MS); m/z: Calc.: 892.923 [C50H28N10O6Si], Found: 892.031 [M]+, 714.361 [M‐C9H6NO3‐2H]+, (Q‐TOF MS); m/z: 893.2146 [M + H]+. Enzyme Inhibition Studies The inhibitory capacity of compounds 1a and 2a was assessed against for four enzymes through concentration‐dependent inhibition studies [33]. Enzymatic substrate degradation rates were continuously tracked using spectrophotometric detection methods [34]. The degree of inhibition exhibited by each test compound was characterized by calculating IC50 parameters, which denote the molar concentration at which enzyme‐catalyzed reactions are diminished to half their baseline velocity [27]. All measurements were performed in triplicate to ensure reproducibility. Uninhibited enzyme preparations served as positive controls, normalized to 100% activity. Individual dose‐response relationships were graphically represented for comparative analysis, and quantitative data underwent statistical evaluation via independent samples t‐testing, with findings communicated as mean values accompanied by standard deviation estimates [35]. Human‐derived acetylcholinesterase and butyrylcholinesterase isolated from equine serum were commercially acquired from Sigma‐Aldrich. The two carbonic anhydrase isoenzymes (hCA I and hCA II) were extracted from red blood cell lysates utilizing affinity‐based liquid chromatography with Sepharose‐4B conjugated to L‐tyrosine‐sulfanilamide ligands. This separation technique achieved remarkable enrichment levels, yielding approximately 1293.3‐fold and 1204.8‐fold concentration increases for hCA I and hCA II, respectively [36]. Carbonic Anhydrase Activity Assay The catalytic activity of carbonic anhydrase (CA) was assessed through an esterase‐based assay, wherein the enzyme catalyzes the hydrolysis of p‐nitrophenyl acetate into p‐nitrophenol and p‐nitrophenolate. The production of p‐nitrophenolate was continuously monitored spectrophotometrically at 348 nm wavelength over a 3 min period maintained at 25°C. To determine the IC50 values for compounds 1a and 2a, enzymatic activity measurements were conducted using a minimum of five distinct molecular concentrations. In the absence of test compounds, the baseline activity of hCA I and hCA II isoenzymes was standardized to 100%. The experimental data were subsequently presented as Activity percentage versus inhibitor concentration plots. The complete reaction mixture, with a total volume of 3.0 mL, comprised 1.4 mL of 0.05 M Tris‐sulfate buffer (pH 7.4), 1 mL of 3 mM 4‐nitrophenyl acetate, 0.5 mL of deionized water, and 0.1 mL of enzyme preparation. A reference measurement was obtained by preparing an identical cuvette without enzyme solution. The inhibitory potential of the molecules was systematically investigated. Each test compound was evaluated in triplicate at every concentration examined. The activity of the control cuvette in the absence of inhibitor was assigned a value of 100%. Activity percentage versus inhibitor concentration relationships were graphically represented for each inhibitory compound [37, 38]. Cholinesterase Activity Assay The inhibitory potential of the investigated compounds (compounds 1a and 2a) against BChE and AChE enzymes was evaluated in vitro using the methodology established by Ellman et al. [39]. Acetylcholine iodide (AChI) and butyrylcholine iodide (BChI) served as the respective substrates for both enzymatic reactions. To quantify the inhibitory effects on BChE and AChE, 5,5′‐dithiobis(2‐nitrobenzoic) acid (DTNB) was employed as the chromogenic reagent. The experimental procedure involved combining 100 μL of buffer solution (pH 8.0, Tris/HCl, 1.0 M) with test compounds dissolved in dimethyl sulfoxide at varying concentrations, followed by the addition of 50 μL of enzyme solution (BChE/AChE, 5.32 × 10−3 EU). Following a 10 min incubation period at 20°C, 50 μL of DTNB (0.5 mM) and 25 µL of the appropriate substrate (BChI or AChI) were introduced to the reaction mixture. Enzyme activity was subsequently quantified spectrophotometrically by measuring absorbance at 412 nm [26, 27]. Materials and equipment, FT‐IR, UV‐Vis, Mass, 1H NMR spectra for the synthesized compounds (Figures S1–S12) and IC50 graphs are presented in the supplementary material. Computational Studies Molecular Docking Studies Protein Preparation The three‐dimensional (3D) crystal structures of human acetylcholinesterase (AChE, PDB ID: 4EY7, resolution: 2.35 Å [40], human butyrylcholinesterase (BChE, PDB ID: 4BDS, resolution: 2.10 Å [41], human carbonic anhydrase I (hCA I, PDB ID: 1AZM, resolution: 2.00 Å [42], and human carbonic anhydrase II (hCA II, PDB ID: 3HS4, resolution: 1.10 Å [43] were retrieved from the RCSB Protein Data Bank (www.rcsb.org). All crystallographic water molecules, co‐crystallized ligands, and ions (except the catalytic zinc ion in carbonic anhydrase structures) were removed. Polar hydrogen atoms were added, and Gasteiger partial charges were assigned to all protein atoms using Open Babel 3.1.0. The prepared protein structures were saved in PDBQT format for docking calculations. Ligand Preparation The two‐dimensional structures of compounds 1a and 2a were drawn and converted to 3D conformations using Open Babel 3.1.0. Energy minimization was performed using the MMFF94 (Merck Molecular Force Field 94) force field with 500 optimization steps to obtain the lowest energy conformers. Gasteiger partial charges were calculated and assigned to all ligand atoms. The optimized ligand structures were saved in PDBQT format for subsequent docking studies. Docking Protocol Molecular docking simulations were performed using AutoDock Vina version 1.2.5. The grid boxes were defined to encompass the active site residues of each target enzyme. For AChE (4EY7), the grid box was centered at coordinates x = −14.1, y = −43.8, z = 27.7 with dimensions of 28 × 30 × 32 Å, covering the catalytic anionic site (CAS) and peripheral anionic site (PAS). For BChE (4BDS), the grid center was set at x = 133.076, y = 116.113, z = 41.335 with dimensions of 30 × 30 × 30 Å. For hCA I (1AZM) and hCA II (3HS4), the grid boxes were centered on the zinc coordination sphere at coordinates x = 34.3, y = 16.4, z = −18.7 and x = −6.720, y = −1.684, z = 15.288, respectively, with dimensions of 40 × 40 × 40 Å to accommodate the large phthalocyanine macrocycle. The Vinardo scoring function was employed for binding affinity calculations, as it has been reported to provide improved accuracy for polar interactions. The exhaustiveness parameter was set to 16 to ensure adequate conformational sampling, and 20 binding modes were generated for each ligand‐protein pair with an energy range of 4 kcal/mol. The docking poses with the lowest binding energies were selected for further analysis and visualization using UCSF ChimeraX version 1.11. To validate the reliability of the docking protocol, a redocking procedure was performed in which the co‐crystallized reference ligand of each target enzyme (donepezil for 4EY7, tacrine for 4BDS, and acetazolamide for 1AZM and 3HS4) was extracted and re‐docked into its respective binding site using the identical Vinardo parameters (Figure 1). The root‐mean‐square deviation (RMSD) between the re‐docked pose and the crystallographic binding mode was calculated over all heavy atoms. Redocking validation of the molecular docking protocol. The co‐crystallized reference ligands (cyan) were re‐docked into their respective binding sites and the resulting poses (purple) were superimposed onto the crystallographic conformations for (A) AChE (4EY7, donepezil), (B) BChE (4BDS, tacrine), (C) hCA I (1AZM, acetazolamide), and (D) hCA II (3HS4, acetazolamide). The close overlap between the re‐docked and crystallographic poses, with RMSD values of 0.49, 0.26, 0.56, and 1.08 Å respectively (all below the 2.0 Å threshold), confirms the reliability of the docking protocol. Structure‐Activity Relationship (SAR) Analysis The structure‐activity relationship of the synthesized silicon phthalocyanine derivatives was evaluated by comparative analysis of compounds 1a and 2a. The molecular properties, including molecular weight, number of hydrogen bond donors and acceptors, and presence of halogen atoms, were compared. The influence of axial substituents (5,7‐dichloro‐8‐hydroxy‐2‐methylquinoline for 1a and N‐(hydroxymethyl)phthalimide for 2a) on enzyme inhibitory activity was assessed by comparing experimental IC50 values and molecular docking scores across all target enzymes. The fold‐change in inhibitory potency was calculated as the ratio of IC50 values (IC50 of 1a/IC50 of 2a) for each enzyme. Density Functional Theory (DFT) Calculations Density functional theory calculations were performed using ORCA 6.1.0 [44] program package to investigate the electronic properties of the synthesized compounds. The geometry‐optimized structures obtained from molecular mechanics (MMFF94) were used as input [45]. Single‐point energy calculations were carried out at the B3LYP/def2‐SVP level of theory with the RIJCOSX approximation for efficient integral evaluation. The frontier molecular orbital energies (HOMO and LUMO) were extracted from the converged wavefunctions. Global reactivity descriptors including ionization potential (I = −EHOMO), electron affinity (A = −ELUMO), chemical hardness (η=(I−A)/2), chemical softness (S=1/2η), electronegativity (χ=(I+A)/2), and electrophilicity index (ω=χ2/2η) were calculated according to Koopmans' theorem and conceptual DFT framework. In Silico ADMET Prediction The absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties of compounds 1a and 2a were predicted using SwissADME [46] and pkCSM [47] web servers. The canonical SMILES representations of the compounds were used as input. Physicochemical properties, including molecular weight, lipophilicity (LogP), topological polar surface area (TPSA), and hydrogen bond donors/acceptors, were calculated. Drug‐likeness was evaluated according to Lipinski's rule of five. Pharmacokinetic parameters, including gastrointestinal absorption, blood‐brain barrier permeability, P‐glycoprotein substrate potential, and cytochrome P450 enzyme inhibition, were predicted. Toxicity endpoints, including hepatotoxicity, skin sensitization, and AMES mutagenicity, were also evaluated. Results and Discussion Synthesis and Spectroscopic Characterization Scheme 1 illustrates the synthesis of 5,7‐Dichloro‐8‐hydroxy‐2‐methylquinoline substituted silicon phthalocyanine (1a) and N‐(hydroxymethyl)phthalimide substituted silicon phthalocyanine (2a). Both derivatives were synthesized by the reaction of SiPcCl2 with the corresponding ligands 5,7‐Dichloro‐8‐hydroxy‐2‐methylquinoline and N‐(hydroxymethyl)phthalimide in the presence of sodium hydride in anhydrous toluene at 110°C. Synthetic route of compounds 1a and 2a. (i) anhydrous toluene, NaH, 110°C, 36 h, Ar atm. The FT‐IR spectra of compounds 1a and 2a confirmed successful axial substitution, as evidenced by the disappearance of the broad ‐OH stretching vibrations characteristic of the ligands' moieties. In the UV‐Vis spectra, the maximum absorption was observed at 690 nm for compound 1a and at 694 nm for compound 2a. Compared to the starting material silicon(IV) phthalocyanine dichloride (SiPcCl2), compound 1a exhibited an 18 nm bathochromic shift while compound 2a showed a 20 nm bathochromic shift. This bathochromic shift relative to SiPcCl2 is attributed to axial ligand exchange at the silicon center: replacement of the electronegative chloride ligands by electron‐donating aryloxy/alkoxy oxygen atoms increases the electron density of the phthalocyanine π‐system and narrows the HOMO‐LUMO gap, shifting the Q‐band to longer wavelength; this is consistent with previous reports that axial substitution perturbs the π‐electronic distribution of the macrocycle through the dipole of the metal‐axial ligand bond [48]. Structural characterization was further supported by mass spectrometric analyses using MALDI‐TOF MS and Q‐TOF MS techniques. In the MALDI‐TOF MS spectrum of compound 1a, the peak at m/z 767.223 corresponding to [M‐C10H6Cl2NO]+ was observed, attributed to the loss of one axial ligand. Compound 2a displayed the molecular ion peak at m/z 892.031 [M]+. These assignments were corroborated by Q‐TOF MS data, confirming the proposed molecular structures. [M + H]+ peaks were observed at m/z 995.1196 and 893.2146 for compounds 1a and 2a respectively. Additional structural evidence was obtained from the 1H NMR spectra. For compound 1a, the Hα protons resonated at 9.44–9.42 ppm, while the Hβ protons appeared in the range of 8.24–8.22 ppm. In the case of compound 2a, the Hα and Hβ protons were observed at 9.65 and 8.34 ppm respectively, consistent with successful axial substitution of the silicon phthalocyanine core. Biological Activity Studies Compounds presented in Scheme 1 were separately tested under in vitro conditions to analyze their anticholinergic actions and their effectiveness as inhibitors of CA isoenzymes (Table 1). Table 1IC50 values of the synthesized compounds against AChE, BChE, hCA I, and hCA II.CompoundAChEBChEhCA IhCA IIIC50 [µM]R2 IC50 [µM]R2 IC50 [µM]R2 IC50 [µM]R2 SiPcCl 2 77.00 ± 12.030.9400732.50 ± 87.120.949114.74 ± 6.060.943453.30 ± 28.650.9395 1a 91.28 ± 25.210.921843.31 ± 20.350.96018.50 ± 2.800.980022.35 ± 12.980.9764 2a 2.78 ± 1.050.96394.88 ± 1.500.94300.94 ± 1.060.91794.15 ± 3.010.9268 Tacrine 36.47 ± 10.100.899152.23 ± 21.970.9901—— Aza ——18.23 ± 8.120.906118.72 ± 7.130.9754Abbreviations: Aza = Acetazolamide: Reference drug for hCA inhibition, Tacrine: Reference drug for cholinesterase inhibition.John Wiley & Sons, Ltd. IC50 values of the synthesized compounds against AChE, BChE, hCA I, and hCA II. Abbreviations: Aza = Acetazolamide: Reference drug for hCA inhibition, Tacrine: Reference drug for cholinesterase inhibition. The synthesized compounds (1a and 2a) were evaluated for their inhibitory effects on acetylcholinesterase (AChE), butyrylcholinesterase (BuChE) and human carbonic anhydrase isoforms I and II (hCA I and hCA II), as shown in Table 1. Among all tested compounds, compound 2a emerged as the most effective multi‐target inhibitor across all enzymatic targets. Compound 2a displayed remarkable potency against hCA I with an IC50 value of 0.94 ± 1.06 µM, which was significantly more effective than the reference drug acetazolamide (IC50 = 18.23 ± 8.12 µM). Compound 1a showed moderate activity against hCA I (IC50 = 8.50 ± 2.80 µM), demonstrating approximately 2.14‐fold stronger inhibition compared to the reference compound. In terms of AChE inhibition, compound 2a proved to be highly effective with an IC50 of 2.78 ± 1.05 µM, substantially outperforming the reference standard tacrine (IC50 = 36.47 ± 10.10 µM). Compound 2a also showed strong BChE inhibitory activity with an IC50 of 4.88 ± 1.50 µM, which was roughly ten times more potent than the reference standard (IC50 = 52.23 ± 21.97 µM). For hCA II inhibition, compound 2a was the most potent inhibitor with an IC50 value of 4.15 ± 3.01 µM, confirming its potential as an effective multi‐target enzyme inhibitor. When all results were evaluated, compound 1a demonstrated moderate inhibitory activity across the enzymatic targets, though it did not achieve the potency levels observed with compound 2a. Molecular Docking Analysis Cholinesterase Inhibition The docking results revealed favorable binding of both compounds within the active site gorge of AChE and BChE. For AChE (PDB: 4EY7), compound 2a exhibited a binding affinity of −8.11 kcal/mol, which was slightly more favorable than compound 1a (−8.04 kcal/mol). The silicon phthalocyanine core of both compounds occupied the peripheral anionic site (PAS) located at the entrance of the active site gorge, while the axial substituents extended toward the catalytic anionic site (CAS) at the bottom of the gorge. The phthalimide groups of compound 2a showed better accommodation within the narrow gorge compared to the bulkier dichloroquinoline moieties of compound 1a, which may explain the superior inhibitory activity of compound 2a (IC50 = 2.78 ± 1.05 µM) compared to compound 1a (IC50 = 91.28 ± 25.21 µM). For BChE (PDB: 4BDS), compound 2a displayed a binding affinity of −3.94 kcal/mol, while compound 1a showed a weaker binding score of −2.53 kcal/mol. The larger active site cavity of BChE compared to AChE allowed better accommodation of the phthalocyanine macrocycle. The docking results are consistent with the experimental findings, where compound 2a (IC50 = 4.88 ± 1.50 µM) exhibited significantly higher inhibitory potency than compound 1a (IC50 = 43.31 ± 20.25 µM). Carbonic Anhydrase Inhibition The docking analysis of compounds 1a and 2a against hCA I (PDB: 1AZM) and hCA II (PDB: 3HS4) demonstrated favorable binding near the catalytic zinc ion. For hCA I, compound 2a showed a binding affinity of −7.39 kcal/mol compared to −7.29 kcal/mol for compound 1a. The phthalocyanine core was positioned at the entrance of the conical active site cavity, with the axial substituents oriented toward the zinc coordination sphere. Similarly, for hCA II, compound 2a exhibited a binding score of −7.15 kcal/mol, which was more favorable than compound 1a (−6.53 kcal/mol) (Figure 2 and Table 2). 3D representation of molecular docking results for compounds 1a and 2a against acetylcholinesterase (AChE, PDB: 4EY7), butyrylcholinesterase (BChE, PDB: 4BDS), human carbonic anhydrase I (hCA I, PDB: 1AZM), and human carbonic anhydrase II (hCA II, PDB: 3HS4). Protein surfaces are rendered in purple with 50% transparency, ligands are shown as ball‐and‐stick models colored by element, and key interacting residues within 4 Å are displayed as sticks with labels. Table 2Molecular Docking Scores of Compounds 1a and 2a Against Target Enzymes.CompoundTargetPDB IDBinding Affinity (kcal/mol) 1a AChE4EY7−8.04 1a BChE4BDS−2.53 1a hCA I1AZM−7.29 1a hCA II3HS4−6.53 2a AChE4EY7−8.11 2a BChE4BDS−3.94 2a hCA I1AZM−7.39 2a hCA II3HS4−7.15John Wiley & Sons, Ltd. Molecular Docking Scores of Compounds 1a and 2a Against Target Enzymes. The superior binding affinities of compound 2a can be attributed to the presence of phthalimide groups, which contain carbonyl functionalities capable of forming hydrogen bonds with active site residues. In contrast, the dichloroquinoline substituents of compound 1a provide limited hydrogen bonding capacity, resulting in weaker interactions. These computational findings correlate well with the experimental IC50 values, where compound 2a demonstrated potent inhibition of hCA I (IC50 = 0.94 ± 1.06 µM) and hCA II (IC50 = 4.15 ± 3.01 µM) compared to compound 1a (IC50 = 8.50 ± 2.80 µM and 22.35 ± 12.98 µM, respectively). The detailed interaction analysis revealed distinct binding patterns for compounds 1a and 2a (Table 3). Notably, compound 2a formed three hydrogen bonds with Arg525, Asp400, and Thr383 in the AChE active site, whereas compound 1a exhibited only van der Waals contacts with the same residues. This difference in hydrogen bonding capacity may contribute to the 25‐fold higher inhibitory potency of compound 2a against AChE. For BChE, compound 1a showed more extensive contacts (18 residues) compared to compound 2a (12 residues); however, the quality of interactions rather than quantity appears to be the determining factor for inhibitory activity. In carbonic anhydrases, compound 2a displayed an electrostatic interaction with His67 in hCA I and established contacts with 15 residues in hCA II, including key residues Trp245, Arg246, and Gln103, whereas compound 1a interacted with only 7 residues in hCA II. These findings suggest that the phthalimide substituents of compound 2a provide superior complementarity with the active site architecture of all target enzymes. Table 3Key interacting residues and interaction types for compounds 1a and 2a with target enzymes (distance cutoff: 4.0 Å).TargetCompoundKey Interacting ResiduesInteraction TypesNumber of ContactsAChE (4EY7) 1a Gln527, Asp384, His381, Arg525, Tyr382, Ala528, Arg393, Ala526Van der Waals12AChE (4EY7) 2a Arg525, Asp400, Thr383, His381, Tyr382, Gln527, Leu380, Asp384Hydrogen bond (3), Van der Waals (9)12BChE (4BDS) 1a Tyr332, Ser287, Asn289, Ala277, Gln119, Ile69, Gln71, Asn68Van der Waals18BChE (4BDS) 2a Glu80, His77, Thr86, Asn85, Ile69, Asp70, Pro84, Gln71Van der Waals12hCA I (1AZM) 1a Pro201, Pro202, His67, Tyr204, Val62, Leu131, Phe91, Gln92Van der Waals, Hydrophobic16hCA I (1AZM) 2a Tyr204, His67, Pro202, Val62, Leu198, Asp72, Asn69, Phe91Electrostatic (1), Van der Waals (14)15hCA II (3HS4) 1a Phe20, Ile22, Pro21, Pro202, Leu204, Asp19Hydrophobic, Van der Waals7hCA II (3HS4) 2a Trp245, Arg246, Gln103, Ser99, Leu100, Asp243, Lys9, Pro247Van der Waals15John Wiley & Sons, Ltd. Key interacting residues and interaction types for compounds 1a and 2a with target enzymes (distance cutoff: 4.0 Å). The docking results demonstrated qualitative agreement with experimental IC50 values, correctly ranking compound 2a as the more potent inhibitor across all targets. However, the modest binding energy differences (0.07–1.41 kcal/mol) did not quantitatively correlate with the experimental potency differences (5.38–32 fold). This discrepancy is well‐documented in molecular docking studies and arises from inherent limitations of scoring functions, which employ simplified treatments of solvation, entropic contributions, and protein flexibility. An additional contributing factor is that both compounds share the same large phthalocyanine macrocycle, which dominates the total binding score and differs only in the axial substituent; consequently, the overall docking energies are numerically similar even though the nature of the substituent‐specific contacts differs substantially. This is clearly reflected in the interaction analysis (Table 3), where compound 2a forms specific hydrogen bonds with active‐site residues while compound 1a engages predominantly through weaker van der Waals contacts. Such qualitative differences in interaction type, rather than the absolute binding‐energy values, provide a more meaningful explanation for the large experimental potency differences. Despite these limitations, the docking analysis provided valuable mechanistic insights, revealing that the phthalocyanine macrocycle occupies peripheral binding regions while axial substituents extend toward catalytic residues. The reliability of the docking protocol was confirmed by a redocking validation, in which the co‐crystallized ligand of each target was re‐docked into its binding site. The protocol accurately reproduced the experimental binding poses, yielding RMSD values of 0.49 Å for AChE (4EY7), 0.26 Å for BChE (4BDS), 0.56 Å for hCA I (1AZM), and 1.08 Å for hCA II (3HS4). As all RMSD values were well below the commonly accepted 2.0 Å threshold, the docking protocol was deemed reliable for predicting the binding modes of the studied compounds. The binding modes reported here were obtained from molecular docking, which provides static representations of ligand–protein complexes and does not account for conformational dynamics or solvent effects over time. Although the docking‐derived poses are consistent with the experimentally observed inhibition trends, their stability under physiological conditions was not assessed in the present study. Molecular dynamics (MD) simulations, which would allow evaluation of the temporal stability of these complexes and the persistence of key interactions, are therefore planned as a follow‐up to further corroborate the proposed binding modes. Structure‐Activity Relationship The comparison of biological activities of compounds 1a and 2a revealed a clear structure‐activity relationship based on the nature of axial substituents (Table 4). Compound 2a, bearing N‐(hydroxymethyl)phthalimide groups, exhibited significantly higher inhibitory activity than compound 1a with 5,7‐dichloro‐8‐hydroxy‐2‐methylquinoline substituents against all target enzymes. The fold improvements were 32.83‐fold for AChE (IC50: 2.78 ± 1.05 vs. 91.28 ± 25.21 µM), 8.8‐fold for BChE (IC50: 4.88 ± 1.50 vs. 43.31 ± 20.35 µM), ninefold for hCA I (IC50: 0.94 ± 1.06 vs 8.50 ± 2.80 µM), and 5.38‐fold for hCA II (IC50: 4.15 ± 3.01 vs. 22.35 ± 12.98 µM). The enhanced activity of compound 2a can be attributed to several structural factors: (i) the lower molecular weight (892.92 vs. 994.75 g/mol) allowing better penetration into active site cavities, (ii) the presence of carbonyl groups providing additional hydrogen bonding opportunities with active site residues, and (iii) the absence of bulky chlorine atoms, reducing steric clashes within the binding sites. The molecular docking results supported these findings, with compound 2a displaying more favorable Vinardo binding scores than compound 1a for all target enzymes (Table 4). These results indicate that the replacement of dichloroquinoline with phthalimide substituents represents a favorable structural modification for enhancing the enzyme inhibitory activity of silicon phthalocyanines. Because this comparison involves only two axially substituted derivatives, the structure‐activity relationships described here are best regarded as qualitative trends rather than firmly established correlations. Even so, the consistent and substantial potency difference observed across all four enzyme targets offers a meaningful basis for rational design. To place these observations on firmer ground, we are currently extending the series with further axial substituents that vary systematically in their electronic and steric character, which should allow the present trends to be confirmed and broadened in scope. Table 4Comparative Analysis of Structural Features and Biological Activities of Compounds 1a and 2a.ParameterCompound 1aCompound 2aEffectMolecular Weight (g/mol)994.75892.92↓ 102H‐Bond Acceptors1216↑ 4Halogen Atoms4 (Cl)0↓ 4AChE IC50 (µM)86.623.4825× ↑BChE IC50 (µM)49.505.459× ↑hCA I IC50 (µM)9.760.8911× ↑hCA II IC50 (µM)23.105.504× ↑John Wiley & Sons, Ltd. Comparative Analysis of Structural Features and Biological Activities of Compounds 1a and 2a. Electronic Properties and Reactivity Descriptors The frontier molecular orbital (FMO) analysis provides valuable insights into the electronic structure and chemical reactivity of the synthesized compounds. Compound 1a exhibited HOMO and LUMO energies of −4.358 eV and −3.693 eV, respectively, with a HOMO‐LUMO energy gap of 0.666 eV. Compound 2a displayed lower HOMO (− 4.670 eV) and LUMO (− 3.789 eV) energies with a slightly larger energy gap of 0.881 eV (Figure 3). The relatively small energy gaps for both compounds indicate high chemical reactivity and ease of electronic transitions, which is characteristic of phthalocyanine macrocycles with extended π‐conjugation. The low ionization potentials (4.358 eV for 1a and 4.670 eV for 2a) suggest that both compounds can readily donate electrons, while the high electron affinities (3.693 eV and 3.789 eV) indicate strong electron‐accepting capability (Table 5). Frontier molecular orbital (HOMO and LUMO) distribution patterns of compounds 1a and 2a obtained from DFT calculations. Table 5Frontier molecular orbital energies and global reactivity descriptors.ParameterCompound 1aCompound 2aE_HOMO (eV)−4.358−4.670E_LUMO (eV)−3.693−3.789ΔE_gap (eV)0.6660.881Ionization Potential, I (eV)4.3584.670Electron Affinity, A (eV)3.6933.789Chemical Hardness, η (eV)0.3330.441Chemical Softness, S (eV−1)1.5031.135Electronegativity, χ (eV)4.0254.229Electrophilicity Index, ω (eV)24.3520.30John Wiley & Sons, Ltd. Frontier molecular orbital energies and global reactivity descriptors. The global reactivity descriptors revealed notable differences between the two compounds. Compound 1a possesses lower chemical hardness (η = 0.333 eV) and higher chemical softness (S = 1.503 eV−1) compared to compound 2a (η = 0.441 eV, S = 1.135 eV−1), indicating a more polarizable electronic structure for compound 1a. However, compound 2a exhibited higher electronegativity (χ = 4.229 eV) compared to compound 1a (χ = 4.025 eV), reflecting the stronger electron‐withdrawing nature of the phthalimide substituents. The electrophilicity index (ω) of compound 1a (24.35 eV) was higher than that of compound 2a (20.30 eV), suggesting greater electrophilic character for compound 1a. Interestingly, despite compound 1a possessing higher chemical softness and electrophilicity, compound 2a demonstrated superior enzyme inhibitory activity across all targets. This observation indicates that molecular geometry, hydrogen bonding capacity, and steric compatibility with enzyme active sites are more critical determinants of biological activity than electronic parameters alone for these macrocyclic compounds. Nevertheless, the FMO and reactivity descriptors complement the biological findings by characterizing the electronic environment in which these interactions occur. The narrow HOMO‐LUMO gaps and high electron affinities of both compounds reflect the polarizable, electron‐rich π‐system of the phthalocyanine core, which facilitates the dispersive and electrostatic contacts observed in the docking analysis. In particular, the higher electronegativity of compound 2a is consistent with the enhanced polar and hydrogen‐bonding interactions identified in its docking poses, providing an electronic rationale that aligns with both the docking results and the experimentally determined IC50 values. Thus, while the global reactivity descriptors are not direct predictors of inhibitory potency, they offer a coherent electronic‐structure framework that supports the structural and docking‐based interpretation of the observed activity trends. ADMET Properties and Drug‐Likeness The in silico ADMET properties of compounds 1a and 2a are summarized in Table 6. Both compounds exhibited high molecular weights (994.75 g/mol for 1a and 892.92 g/mol for 2a) exceeding the Lipinski threshold of 500 Da. The calculated LogP values (8.45 for 1a and 6.12 for 2a) and TPSA values (143.52 Å2 for 1a and 167.89 Å2 for 2a) resulted in three Lipinski rule violations for both compounds, which is characteristic of phthalocyanine macrocycles. The pharmacokinetic predictions indicated low gastrointestinal absorption and no blood‐brain barrier penetration for both compounds. Both were predicted to be P‐glycoprotein substrates and CYP3A4 inhibitors. Compound 2a additionally showed potential CYP2C19 inhibition. Importantly, both compounds displayed favorable toxicity profiles. Neither compound was predicted to be hepatotoxic or mutagenic (AMES negative). Compound 1a showed potential skin sensitization due to halogen atoms, while compound 2a was predicted to be non‐sensitizing. Both compounds were classified in toxicity class IV (LD50: 2.45 and 2.62 mol/kg), indicating relatively low acute toxicity. It should be emphasized that Lipinski's rule of five was originally formulated to predict the oral bioavailability of small‐molecule drugs and is not applicable to macrocyclic scaffolds such as phthalocyanines, which inherently exceed these thresholds owing to their extended π‐conjugated framework. Consistent with other macrocyclic and large‐molecule therapeutics, phthalocyanines are conventionally administered via parenteral or topical routes rather than oral delivery; indeed, several clinically employed phthalocyanine‐ and porphyrin‐based photosensitizers are delivered by injection. Accordingly, the observed Lipinski violations reflect the intrinsic physicochemical nature of the phthalocyanine class rather than a genuine liability, and do not preclude the therapeutic potential of compounds 1a and 2a. The favorable toxicity profiles and potent enzyme inhibitory activities support further development of these compounds, with compound 2a showing superior ADMET characteristics due to lower lipophilicity and absence of skin sensitization. Collectively, the computational analyses support compound 2a as the more promising candidate for further development, exhibiting not only superior enzyme inhibitory activity but also more favorable ADMET characteristics including lower lipophilicity and absence of skin sensitization potential. While the present ADMET analysis provides a useful preliminary assessment, the reported values stem from computational models rather than experimental assays. The predictions, therefore, serve to guide rather than confirm the pharmacokinetic and toxicity behavior of the compounds, and follow‐up in vitro and in vivo studies will be necessary to substantiate these findings. Table 6Predicted ADMET properties of compounds 1a and 2a.PropertyCompound 1aCompound 2aMolecular Weight (g/mol)994.75892.92Consensus LogP8.456.12TPSA (Å2)143.52167.89H‐Bond Donors00H‐Bond Acceptors1216Rotatable Bonds46Lipinski Violations33GI AbsorptionLowLowBBB PermeationNoNoP‐gp SubstrateYesYesCYP1A2 InhibitorNoNoCYP2C19 InhibitorNoYesCYP2C9 InhibitorNoNoCYP2D6 InhibitorNoNoCYP3A4 InhibitorYesYesAMES ToxicityNoNoHepatotoxicityNoNoSkin SensitizationYesNoLD50 (mol/kg)2.452.62Toxicity ClassIVIVJohn Wiley & Sons, Ltd. Predicted ADMET properties of compounds 1a and 2a. Conclusion Two novel axially substituted silicon phthalocyanines bearing quinoline (1a) and phthalimide (2a) moieties were successfully synthesized and characterized using spectroscopic techniques. The enzyme inhibition studies revealed that both compounds exhibited inhibitory activity against acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and human carbonic anhydrase isoenzymes I and II (hCA I and hCA II). Compound 2a demonstrated significantly superior inhibitory potency across all tested enzymes compared to compound 1a. The enhanced biological activity of compound 2a can be attributed to the presence of phthalimide axial substituents, which provide additional hydrogen bonding capability and improved steric compatibility with the enzyme active sites. Molecular docking studies supported the experimental findings, revealing more favorable binding affinities and interaction patterns for compound 2a, particularly within the active site regions of cholinesterases and carbonic anhydrases. Consistent with the molecular docking results, structure‐activity relationship analysis revealed that compound 2a exhibits higher inhibitory activity compared to 1a. Furthermore, density functional theory calculations highlighted differences in the electronic properties of the two silicon phthalocyanines, while in silico ADMET analyses indicated acceptable toxicity profiles for both compounds, with compound 2a exhibiting more favorable pharmacokinetic characteristics, including lower lipophilicity and absence of predicted skin sensitization. Overall, the combined experimental and computational results identify compound 2a as a promising multifunctional enzyme inhibitor and underline the importance of axial substitution in modulating the biological performance of silicon phthalocyanines. These findings provide a useful framework for the rational design of next‐generation phthalocyanine‐based enzyme inhibitors. Author Contributions Seda Ünlü: conceptualization, investigation, resources, writing – original draft, writing – review and editing. Zeynep Köksal: conceptualization, investigation, writing – original draft, writing – review and editing, resources. Kevser Kübra Kırboğa: investigation, Seda Ünlüeda Ünlüoftware, writing – original draft. Fikriye Tuncel Elmalı: conceptualization, investigation, writing – review and editing, resources, Seda Ünlüeda Ünlüupervision. Conflicts of Interest The authors declare no conflicts of interest. Supporting information Supporting File